Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Funding Rounds (2) - $34.2MUpdate
Current Team (4)Update
|Jan 7, 2016||Xconomy - Former Cubist CEO Mike Bonney Joins Third Rock Ventures|
|Jun 2, 2015||Business Wire - Dimension Therapeutics Announces Expansion of Management Team as Company Advances Lead Programs toward the Clinic|
|Oct 20, 2014||Xconomy - Cubist CEO Bonney Steps Down After 12-Year Stint|
|Apr 22, 2014||Xconomy - 7 Takeaways From “What’s Hot in Boston Biotech”|
|Nov 21, 2013||Xconomy - Flagship Takes a Stab at Microbiome Therapy With Seres Health|
|Sep 6, 2013||Xconomy - East Coast Life Sciences Roundup: Aileron, Enzymatics, Acton, & More|
|Jul 30, 2013||firstwordpharma.com - Cubist to buy Trius Therapeutics, Optimer Pharmaceuticals for up to $1.6 billion|
|Jul 30, 2013||Business Wire - Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals|
10110 Sorrento Valley Rd.
San Diego, CA 92121
65 Hayden Avenue
Lexington, MA 02421